News

Resources

Publications

New research publication: First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants.

Read More

Optimization of therapeutic antibodies.

Read More

ARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2.

Read More

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.

Read More

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.

Read More

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA